AVANT Immunotherapeutics, Inc. has signed a license agreement with DynPort Vaccine Company LLC (DVC) for exclusive rights to use certain components of AVANT’s vaccine technology. DVC, a private company, is chartered with providing an integrated approach for the advanced development of specific vaccines and other products to protect against the threat of biological warfare agents. Read more about Avant Licenses Vaccine Technology[…]
Neurochem, Inc. and SELECT Therapeutics, Inc. have announced the initiation of a collaboration program to advance a novel vaccine intended to prevent the development and the progression of Alzheimer’s Disease. The vaccine will target the prevention of an accumulation of beta- amyloid, a protein that constitutes a major part of plaques in the brain of Read more about Neurochem And SELECT Therapeutics Collaborate On Alzheimer’s Vaccine[…]
Anadys Pharmaceuticals, Inc. and Gilead Sciences, Inc. have entered into a collaboration to discover novel antiviral compounds. As part of the collaboration agreement, Anadys will design, configure and run uHTS-ATLAS screens against a key viral target selected by Gilead. This agreement leverages Anadys’ powerful ability to screen for small molecules that bind to proteins that Read more about Anadys Forms Collaboration With Gilead[…]
Phylogix, Inc. and Large Scale Biology Corporation have formed a bioprocessing alliance to develop and manufacture Phylogix, Inc.’s lead therapeutic protein, a native protein in hyacinth seeds called FRIL. The protein represents a novel chemoprotective agent that, in animals, has demonstrated a unique ability to protect normal tissues from the toxic side effects of chemotherapy. Read more about LSBC And Phylogix Form Bioprocessing Alliance[…]
Cerylid Biosciences Limited and Anadys Pharmaceuticals, Inc. have announced a strategic partnership for the discovery of novel anti-infective compounds. This partnership will utilize Anadys’ uHTS-ATLAS technology to screen Cerylid’s world leading collection of natural products against key Anadys targets. Under the terms of the collaboration, Anadys will gain access to Cerylid’s extensive library of unique Read more about Cerylid, Anadys Sign Anti-infective Collaboration[…]
ViroLogic Inc. has signed an expanded agreement with Pfizer Inc. to use ViroLogic’s HIV resistance testing technology for Pfizer’s HIV drug discovery and development programs.ViroLogic said the new pact covers work performed for all of Pfizer’s global research and development sites worldwide. As recommended by the FDA’s antiviral drugs advisory committee, biopharmaceutical companies are using Read more about Virologic Expands Pact With Pfizer[…]
Centocor, Inc., a Johnson & Johnson company, has expanded its earlier license and option agreement to use Vical‘s Incorporated naked DNA technology to develop and commercialize certain DNA vaccines for the potential treatment of some types of cancer. Vical will receive an undisclosed upfront payment and could receive additional milestone payments in the future. The Read more about Centocor Expands Cancer Vaccine Agreement[…]
Impax Laboratories Inc., which has recently won tentative approval from the FDA for a generic version of Claritin tablets, has signed a “semi-exclusive” development, license and supply agreement with Wyeth for this drug. Claritin is marketed by Schering-Plough Corp. for the relief of symptoms of seasonal allergic rhinitis, or hay fever. Worldwide sales of the Read more about Impax Announces Otc Alliance With Wyeth[…]
GeneFormatics Inc. and Arakis Limited have announced a collaborative agreement for the joint discovery of Performance Enhanced Medicines (PEMs). PEMs are novel pharmaceutical products created using advances in biology to identify applications of established drugs in new indications. Additional clinical and patient benefit is provided using a diverse range of pharmaceutical technologies primarily drug delivery Read more about GeneFormatics Inc. And Arakis Agree Drug Discovery Collaboration[…]
Seattle Genetics, Inc. has recieved a license fee in an undisclosed amount from Genencor International, Inc. under the terms of a strategic alliance formed by the two companies in January 2002. The collaboration involves the joint discovery and development of a class of cancer therapeutics based on tumor-targeted enzymes that activate prodrugs. At the time Read more about Seattle Genetics Receives License Fee From Genencor[…]